Partnership to expand access to Brukinsa in low- and middle-income countries

Sino-American oncology-focused biotech BeOne Medicines (Nasdaq: ONC; HKEX: 06160), together with the BeOne Care Foundation, a non-profit charitable foundation, and The Max Foundation, a global health non-profit organization, have announced the renewal of their partnership through 2028 to expand access to Brukinsa (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively.

Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to Brukinsa for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by around 150 patients and helping establish access to innovative cancer care for patients who previously had limited or no treatment options.